Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection
Passive immunotherapy with monoclonal antibodies (mAbs) is an efficacious treatment for Ebola virus (EBOV) infections in animal models and humans. Understanding what constitutes a protective response is critical for the development of novel therapeutic strategies. We generated an EBOV-glycoprotein-pseudotyped Human immunodeficiency virus to develop sensitive neutralizing and antibody-dependent cellular cytotoxicity (ADCC) assays as well as a bioluminescent-imaging-based mouse infection model that does not require biosafety level 4 containment. The in vivo treatment efficiencies of three novel anti-EBOV mAbs at 12 h post-infection correlated with their in vitro anti-EBOV ADCC activities, without neutralizing activity. When they were treated with these mAbs, natural killer cell (NK)-deficient mice had lower viral clearance than WT mice, indicating that the anti-EBOV mechanism of the ADCC activity of these mAbs is predominantly mediated by NK cells. One potent anti-EBOV mAb (M318) displayed unprecedented neutralizing and ADCC activities (neutralization IC50, 0.018 μg/ml; ADCC EC50, 0.095 μg/ml). These results have important implications for the efficacy of antiviral drugs and vaccines as well as for pathogenicity studies of EBOV.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2017 |
---|---|
Erschienen: |
2017 |
Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
---|---|
Enthalten in: |
Scientific reports - 7(2017) vom: 30. März, Seite 45552 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Liu, Qiang [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antibodies, Monoclonal |
---|
Anmerkungen: |
Date Completed 11.12.2018 Date Revised 11.12.2018 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1038/srep45552 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM27046462X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM27046462X | ||
003 | DE-627 | ||
005 | 20231226193749.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231224s2017 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/srep45552 |2 doi | |
028 | 5 | 2 | |a pubmed24n0901.xml |
035 | |a (DE-627)NLM27046462X | ||
035 | |a (NLM)28358050 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Liu, Qiang |e verfasserin |4 aut | |
245 | 1 | 0 | |a Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection |
264 | 1 | |c 2017 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 11.12.2018 | ||
500 | |a Date Revised 11.12.2018 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Passive immunotherapy with monoclonal antibodies (mAbs) is an efficacious treatment for Ebola virus (EBOV) infections in animal models and humans. Understanding what constitutes a protective response is critical for the development of novel therapeutic strategies. We generated an EBOV-glycoprotein-pseudotyped Human immunodeficiency virus to develop sensitive neutralizing and antibody-dependent cellular cytotoxicity (ADCC) assays as well as a bioluminescent-imaging-based mouse infection model that does not require biosafety level 4 containment. The in vivo treatment efficiencies of three novel anti-EBOV mAbs at 12 h post-infection correlated with their in vitro anti-EBOV ADCC activities, without neutralizing activity. When they were treated with these mAbs, natural killer cell (NK)-deficient mice had lower viral clearance than WT mice, indicating that the anti-EBOV mechanism of the ADCC activity of these mAbs is predominantly mediated by NK cells. One potent anti-EBOV mAb (M318) displayed unprecedented neutralizing and ADCC activities (neutralization IC50, 0.018 μg/ml; ADCC EC50, 0.095 μg/ml). These results have important implications for the efficacy of antiviral drugs and vaccines as well as for pathogenicity studies of EBOV | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
650 | 7 | |a Antibodies, Viral |2 NLM | |
700 | 1 | |a Fan, Changfa |e verfasserin |4 aut | |
700 | 1 | |a Li, Qianqian |e verfasserin |4 aut | |
700 | 1 | |a Zhou, Shuya |e verfasserin |4 aut | |
700 | 1 | |a Huang, Weijin |e verfasserin |4 aut | |
700 | 1 | |a Wang, Lan |e verfasserin |4 aut | |
700 | 1 | |a Sun, Chunyun |e verfasserin |4 aut | |
700 | 1 | |a Wang, Meng |e verfasserin |4 aut | |
700 | 1 | |a Wu, Xi |e verfasserin |4 aut | |
700 | 1 | |a Ma, Jian |e verfasserin |4 aut | |
700 | 1 | |a Li, Baowen |e verfasserin |4 aut | |
700 | 1 | |a Xie, Liangzhi |e verfasserin |4 aut | |
700 | 1 | |a Wang, Youchun |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 7(2017) vom: 30. März, Seite 45552 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
773 | 1 | 8 | |g volume:7 |g year:2017 |g day:30 |g month:03 |g pages:45552 |
856 | 4 | 0 | |u http://dx.doi.org/10.1038/srep45552 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 7 |j 2017 |b 30 |c 03 |h 45552 |